Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma Cells

1 Nov 2019

Abstract excerpt

INTRODUCTION: Glioblastoma (GBM) is the most commonly diagnosed primary brain tumor in adults. The 14.6 months median survival period of GBM patients is still palliative due to resistance to the first-line chemotherapeutic agent temozolomide (TMZ). METHODS: The cell growth inhibition effect was assessed using the SRB assay. The mRNA expression levels were examined using RT-qPCR. The protein expression levels were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31819508
DOI: 10.2147/ott.s221025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma CellsPMID 31819508Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastomaSemantic proximity Read ↗

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read ↗

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read ↗

Molecular mechanisms of temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastomaSemantic proximity Read ↗

PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomideSemantic proximity Read ↗

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read ↗

Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in GlioblastomaSemantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaSemantic proximity Read ↗

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.